[go: up one dir, main page]

EA201391154A3 - Способы и композиции для нацеливания на адипоциты у млекопитающих - Google Patents

Способы и композиции для нацеливания на адипоциты у млекопитающих

Info

Publication number
EA201391154A3
EA201391154A3 EA201391154A EA201391154A EA201391154A3 EA 201391154 A3 EA201391154 A3 EA 201391154A3 EA 201391154 A EA201391154 A EA 201391154A EA 201391154 A EA201391154 A EA 201391154A EA 201391154 A3 EA201391154 A3 EA 201391154A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
mammals
adiscing
adipocytes
Prior art date
Application number
EA201391154A
Other languages
English (en)
Other versions
EA201391154A2 (ru
Inventor
Михаил Г. Колонин
Алексес Даквинаг
Ян Чжан
Original Assignee
Борд Оф Реджентс Оф Зе Юниверсити Оф Тексас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Борд Оф Реджентс Оф Зе Юниверсити Оф Тексас Систем filed Critical Борд Оф Реджентс Оф Зе Юниверсити Оф Тексас Систем
Publication of EA201391154A2 publication Critical patent/EA201391154A2/ru
Publication of EA201391154A3 publication Critical patent/EA201391154A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Предложены способы и композиции для применения в диагностике, визуализации или нацеливании терапевтических агентов для лечения ожирения/связанных с адипозом нарушений, причем указанные композиции и способы позволяют идентифицировать и применять пептиды для селективного нацеливания на жировые стромальные клетки у млекопитающих как in vitro, так и in vivo.
EA201391154A 2011-03-30 2012-03-30 Способы и композиции для нацеливания на адипоциты у млекопитающих EA201391154A3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469345P 2011-03-30 2011-03-30
PCT/US2012/031623 WO2012135729A2 (en) 2011-03-30 2012-03-30 Methods and compositions for targeting adipose cells in mammals

Publications (2)

Publication Number Publication Date
EA201391154A2 EA201391154A2 (ru) 2014-06-30
EA201391154A3 true EA201391154A3 (ru) 2016-01-29

Family

ID=46932409

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391154A EA201391154A3 (ru) 2011-03-30 2012-03-30 Способы и композиции для нацеливания на адипоциты у млекопитающих

Country Status (13)

Country Link
US (2) US9029321B2 (ru)
EP (1) EP2704736A4 (ru)
JP (1) JP2014510758A (ru)
KR (1) KR20140026408A (ru)
CN (1) CN103703140B (ru)
AU (1) AU2012236199A1 (ru)
BR (1) BR112013024467A2 (ru)
CA (1) CA2830375A1 (ru)
EA (1) EA201391154A3 (ru)
IL (1) IL228617A0 (ru)
MX (1) MX2013011294A (ru)
SG (1) SG193317A1 (ru)
WO (1) WO2012135729A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123576A2 (en) * 2014-02-17 2015-08-20 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
CN104774245A (zh) * 2014-08-22 2015-07-15 天津药物研究院 一种脑靶向肽与抗肿瘤药偶联物的制备及应用
CN114558111A (zh) * 2014-11-03 2022-05-31 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物
US10349116B2 (en) 2014-12-29 2019-07-09 DISH Technologies L.L.C. Systems and methods for pre-caching media content in response to user-system interaction
CN104928320B (zh) * 2015-07-03 2018-06-01 中国医学科学院医学生物学研究所 一种携带恒河猴抵抗素剪接体基因慢病毒载体的构建方法
CN108289734B (zh) * 2015-08-17 2024-06-18 约翰·霍普金斯大学 用于组织恢复的间充质细胞结合复合材料
CN106883299A (zh) * 2015-12-16 2017-06-23 杭州阿德莱诺泰制药技术有限公司 脂肪组织靶向多肽及其制备方法和应用
CN106749524B (zh) * 2016-12-05 2020-08-18 华南理工大学 一种抗肥胖七肽npvwkrk
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver
CN107569679B (zh) * 2017-09-06 2020-10-16 首都医科大学附属北京同仁医院 Ace2在调控棕色脂肪组织活性中的应用
CN107496900B (zh) * 2017-09-06 2020-10-16 首都医科大学附属北京同仁医院 一种调控棕色脂肪组织活性的方法
CN107996826A (zh) * 2017-10-27 2018-05-08 威海同丰海洋生物科技有限公司 一种含有防御素的饲料添加剂及其制备方法
CN109276704A (zh) * 2017-11-07 2019-01-29 江苏省中医药研究院 蜂毒肽在制备治疗和/或预防糖尿病的药物或保健品中的用途
US20200368174A1 (en) * 2018-02-21 2020-11-26 Texas Tech University System Particles for targeted delivery of active agents into adipose stromal cells
CN109402102B (zh) * 2018-11-09 2021-12-03 临沂大学 一种表面附有半透保护膜的酶-磷脂微囊的制备方法
KR102143531B1 (ko) * 2018-12-20 2020-08-12 영남대학교 산학협력단 탈리도마이드를 유효성분으로 함유하는 가축 육질 개선용 조성물
KR102112702B1 (ko) * 2019-12-19 2020-05-19 (주)슈퍼노바 바이오 표면 개질된 가스-생성 나노입자를 이용한 지방 분해용 조성물
CN115003285B (zh) * 2020-01-15 2024-05-14 超新星生物有限公司 用于减少局部脂肪的气体发泡型胶束
AU2021252906A1 (en) * 2020-04-07 2022-12-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Anti-obesity peptides and uses thereof
WO2023014375A1 (en) * 2021-08-06 2023-02-09 Lean Life Sciences, Inc Cosmetic peptides for improving skin rejuvenation
CN115463225A (zh) * 2022-09-23 2022-12-13 中国科学院长春应用化学研究所 一种基于脂肪细胞膜凋亡伪装修饰的免疫减肥方法
WO2024117688A1 (ko) * 2022-11-30 2024-06-06 한양대학교 산학협력단 신규한 서열의 펩타이드 및 글리시리진을 포함하는 접합체 및 이를 포함하는 비만의 예방 또는 치료용 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074747A1 (en) 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
JP2004529621A (ja) * 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
WO2008143679A2 (en) 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
US8709772B2 (en) 2008-01-03 2014-04-29 Verenium Corporation Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
CN101970679B (zh) 2008-01-03 2015-04-22 嘉吉公司 氨基转移酶和氧化还原酶核酸和多肽和使用方法
MX2011004270A (es) 2008-10-23 2011-07-13 Basf Plant Science Gmbh Plantas con rendimiento aumentado (nue).
CN102120034B (zh) * 2010-04-23 2015-02-11 江苏省人民医院 一种靶向至棕色脂肪组织治疗肥胖的新型靶向药物
CN102120755B (zh) * 2010-04-23 2013-04-03 江苏省人民医院 一种棕色脂肪组织靶向性多肽及其应用
WO2012169911A1 (en) * 2011-06-10 2012-12-13 Auckland Uniservices Limited Peptides, constructs and uses therefor

Also Published As

Publication number Publication date
US9539341B2 (en) 2017-01-10
JP2014510758A (ja) 2014-05-01
US20160000930A1 (en) 2016-01-07
CA2830375A1 (en) 2012-10-04
SG193317A1 (en) 2013-10-30
CN103703140A (zh) 2014-04-02
US9029321B2 (en) 2015-05-12
EP2704736A2 (en) 2014-03-12
WO2012135729A2 (en) 2012-10-04
US20140243258A1 (en) 2014-08-28
BR112013024467A2 (pt) 2019-09-24
MX2013011294A (es) 2014-10-06
WO2012135729A9 (en) 2014-01-30
KR20140026408A (ko) 2014-03-05
EP2704736A4 (en) 2016-07-20
IL228617A0 (en) 2013-12-31
EA201391154A2 (ru) 2014-06-30
CN103703140B (zh) 2017-02-22
AU2012236199A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
EA201391154A3 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
EA201590115A8 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
UA107814C2 (ru) Спирооксиндольные антагонисты mdm 2
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
MX339709B (es) Antagonistas de wnt y metodos de tratamiento y analisis.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
MX2013004061A (es) Analogos de ciclosporina.
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
MX2013004062A (es) Analogos de ciclosporina.